NCT06076772View on ClinicalTrials.gov

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Not yet recruitingOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Palbociclib

The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors

Trial Locations (1)

11564

Asmaa Imam Ahmed, Al Madīnah

All Listed Sponsors
lead

Assiut University

OTHER

NCT06076772 - Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter